BR112022017210A2 - Compostos e métodos para modulação de splicing - Google Patents
Compostos e métodos para modulação de splicingInfo
- Publication number
- BR112022017210A2 BR112022017210A2 BR112022017210A BR112022017210A BR112022017210A2 BR 112022017210 A2 BR112022017210 A2 BR 112022017210A2 BR 112022017210 A BR112022017210 A BR 112022017210A BR 112022017210 A BR112022017210 A BR 112022017210A BR 112022017210 A2 BR112022017210 A2 BR 112022017210A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- methods
- splicing
- splicing modulation
- modulation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Replacement Of Web Rolls (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Psychology (AREA)
- Saccharide Compounds (AREA)
Abstract
COMPOSTOS E MÉTODOS PARA MODULAÇÃO DE SPLICING. A presente invenção refere-se a compostos e composições relacionadas que, entre outros, modulam splicing de ácido nucleico, por exemplo, splicing de um pré-mRNA, assim como métodos de uso dos mesmos.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062983541P | 2020-02-28 | 2020-02-28 | |
US202063007333P | 2020-04-08 | 2020-04-08 | |
US202063040484P | 2020-06-17 | 2020-06-17 | |
US202063072790P | 2020-08-31 | 2020-08-31 | |
US202063126492P | 2020-12-16 | 2020-12-16 | |
PCT/US2021/020153 WO2021174164A1 (en) | 2020-02-28 | 2021-02-28 | Compounds and methods for modulating splicing |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022017210A2 true BR112022017210A2 (pt) | 2022-10-25 |
Family
ID=75143749
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022017210A BR112022017210A2 (pt) | 2020-02-28 | 2021-02-28 | Compostos e métodos para modulação de splicing |
BR112022017188A BR112022017188A2 (pt) | 2020-02-28 | 2021-02-28 | Amidas heterocíclicas e seu uso para modulação de splicing |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022017188A BR112022017188A2 (pt) | 2020-02-28 | 2021-02-28 | Amidas heterocíclicas e seu uso para modulação de splicing |
Country Status (14)
Country | Link |
---|---|
US (2) | US20230365566A1 (pt) |
EP (3) | EP4110785A1 (pt) |
JP (2) | JP2023515621A (pt) |
KR (2) | KR20220159386A (pt) |
CN (2) | CN115515679A (pt) |
AU (2) | AU2021228767A1 (pt) |
BR (2) | BR112022017210A2 (pt) |
CA (2) | CA3169709A1 (pt) |
CL (2) | CL2022002342A1 (pt) |
CO (2) | CO2022013827A2 (pt) |
CR (2) | CR20220484A (pt) |
IL (2) | IL295956A (pt) |
MX (2) | MX2022010683A (pt) |
WO (3) | WO2021174163A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3689863A1 (en) | 2017-08-04 | 2020-08-05 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
EP4149937A1 (en) | 2020-05-13 | 2023-03-22 | CHDI Foundation, Inc. | Htt modulators for treating huntington's disease |
IL311132A (en) | 2021-08-30 | 2024-04-01 | Remix Therapeutics Inc | Splicing Modulation Compounds and Methods |
WO2023034812A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
CA3238090A1 (en) * | 2021-11-17 | 2023-05-25 | Chdi Foundation, Inc. | Htt modulators for treating huntington's disease |
WO2023244996A2 (en) * | 2022-06-15 | 2023-12-21 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
WO2024086570A1 (en) | 2022-10-17 | 2024-04-25 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
WO2024086569A1 (en) | 2022-10-17 | 2024-04-25 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4809656B2 (ja) * | 2005-09-29 | 2011-11-09 | 富士フイルム株式会社 | ナフタロシアニン色素およびその製造方法 |
TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
SI2049491T1 (sl) * | 2006-08-08 | 2011-05-31 | Millennium Pharm Inc | Heteroarilne spojine uporabne kot inhibitorji e1 aktivirajoäśih encimov |
WO2008040951A1 (en) * | 2006-10-03 | 2008-04-10 | Astrazeneca Ab | Compounds |
WO2009141386A1 (en) * | 2008-05-23 | 2009-11-26 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
EP2435421A1 (en) * | 2009-05-29 | 2012-04-04 | Schering Corporation | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c |
CN102020643A (zh) * | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
TW201202230A (en) * | 2010-05-24 | 2012-01-16 | Mitsubishi Tanabe Pharma Corp | Novel quinazoline compound |
JP6092897B2 (ja) | 2012-02-10 | 2017-03-08 | ピーティーシー セラピューティクス, インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
CA2872989A1 (en) * | 2012-05-09 | 2013-11-14 | Zoetis Llc | Azetidine derivatives as antiparasitic agents |
MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
US9675697B2 (en) * | 2013-03-11 | 2017-06-13 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
KR20140125061A (ko) * | 2013-04-18 | 2014-10-28 | (주)경인양행 | 유기발광 화합물 및 이를 포함하는 유기전계발광소자 |
WO2016004254A1 (en) * | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
CN104341403B (zh) * | 2014-10-10 | 2016-06-22 | 山东盛华电子新材料有限公司 | 一种2,5-二杂环取代萘基噁烷衍生物及其制备方法 |
WO2016128343A1 (en) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment of cancer |
EP3287463A4 (en) * | 2015-04-24 | 2018-07-11 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |
US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
CN110946865B (zh) | 2015-12-10 | 2024-01-26 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
US20190119236A1 (en) * | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
CA3043755A1 (en) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
CA3065547A1 (en) | 2017-06-14 | 2018-12-20 | Ptc Therapeutics, Inc. | Methods for modifying rna splicing |
EP3689863A1 (en) | 2017-08-04 | 2020-08-05 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
CN111373057A (zh) | 2017-09-25 | 2020-07-03 | 斯基霍克疗法公司 | 用于筛选和鉴定剪接调节剂的方法和组合物 |
KR20200142039A (ko) | 2018-04-10 | 2020-12-21 | 스카이호크 테라퓨틱스, 인코포레이티드 | 암 치료용 화합물 |
EP3816160A4 (en) * | 2018-06-27 | 2022-03-16 | Reborna Biosciences, Inc. | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY |
CN109180690A (zh) * | 2018-10-15 | 2019-01-11 | 烟台显华化工科技有限公司 | 一类用作蓝色荧光材料的氮杂芳香化合物及其应用 |
-
2021
- 2021-02-28 CA CA3169709A patent/CA3169709A1/en active Pending
- 2021-02-28 IL IL295956A patent/IL295956A/en unknown
- 2021-02-28 MX MX2022010683A patent/MX2022010683A/es unknown
- 2021-02-28 CA CA3169691A patent/CA3169691A1/en active Pending
- 2021-02-28 IL IL295957A patent/IL295957A/en unknown
- 2021-02-28 EP EP21713822.1A patent/EP4110785A1/en active Pending
- 2021-02-28 KR KR1020227033660A patent/KR20220159386A/ko unknown
- 2021-02-28 AU AU2021228767A patent/AU2021228767A1/en active Pending
- 2021-02-28 WO PCT/US2021/020152 patent/WO2021174163A1/en unknown
- 2021-02-28 US US17/802,719 patent/US20230365566A1/en active Pending
- 2021-02-28 WO PCT/US2021/020154 patent/WO2021174165A1/en active Application Filing
- 2021-02-28 BR BR112022017210A patent/BR112022017210A2/pt unknown
- 2021-02-28 CR CR20220484A patent/CR20220484A/es unknown
- 2021-02-28 EP EP21713824.7A patent/EP4110459A1/en active Pending
- 2021-02-28 MX MX2022010684A patent/MX2022010684A/es unknown
- 2021-02-28 CN CN202180030671.0A patent/CN115515679A/zh active Pending
- 2021-02-28 EP EP21713823.9A patent/EP4110464A1/en active Pending
- 2021-02-28 WO PCT/US2021/020153 patent/WO2021174164A1/en active Application Filing
- 2021-02-28 JP JP2022552209A patent/JP2023515621A/ja active Pending
- 2021-02-28 CN CN202180031467.0A patent/CN115485025A/zh active Pending
- 2021-02-28 AU AU2021228284A patent/AU2021228284A1/en active Pending
- 2021-02-28 CR CR20210483A patent/CR20210483A/es unknown
- 2021-02-28 US US17/802,833 patent/US20240190879A1/en active Pending
- 2021-02-28 KR KR1020227033663A patent/KR20220158238A/ko unknown
- 2021-02-28 JP JP2022552208A patent/JP2023515620A/ja active Pending
- 2021-02-28 BR BR112022017188A patent/BR112022017188A2/pt unknown
-
2022
- 2022-08-26 CL CL2022002342A patent/CL2022002342A1/es unknown
- 2022-08-26 CL CL2022002341A patent/CL2022002341A1/es unknown
- 2022-09-27 CO CONC2022/0013827A patent/CO2022013827A2/es unknown
- 2022-09-27 CO CONC2022/0013832A patent/CO2022013832A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2022002342A1 (es) | 2023-03-17 |
CR20220484A (es) | 2022-12-15 |
IL295957A (en) | 2022-10-01 |
EP4110459A1 (en) | 2023-01-04 |
AU2021228284A1 (en) | 2022-09-29 |
CO2022013832A2 (es) | 2022-10-31 |
EP4110464A1 (en) | 2023-01-04 |
WO2021174165A1 (en) | 2021-09-02 |
CL2022002341A1 (es) | 2023-03-10 |
US20240190879A1 (en) | 2024-06-13 |
JP2023515621A (ja) | 2023-04-13 |
MX2022010683A (es) | 2023-01-19 |
KR20220158238A (ko) | 2022-11-30 |
CR20210483A (es) | 2022-11-25 |
CO2022013827A2 (es) | 2022-10-31 |
MX2022010684A (es) | 2023-01-19 |
BR112022017188A2 (pt) | 2022-11-08 |
KR20220159386A (ko) | 2022-12-02 |
CN115515679A (zh) | 2022-12-23 |
CA3169691A1 (en) | 2021-09-02 |
WO2021174163A1 (en) | 2021-09-02 |
CN115485025A (zh) | 2022-12-16 |
US20230365566A1 (en) | 2023-11-16 |
JP2023515620A (ja) | 2023-04-13 |
WO2021174164A1 (en) | 2021-09-02 |
AU2021228767A1 (en) | 2022-09-29 |
CA3169709A1 (en) | 2021-09-02 |
EP4110785A1 (en) | 2023-01-04 |
IL295956A (en) | 2022-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022017210A2 (pt) | Compostos e métodos para modulação de splicing | |
BR112022017107A2 (pt) | Derivados de piridazina para modulação de splicing de ácido nucleico | |
BR112022020418A2 (pt) | Compostos e métodos para modulação de splicing | |
BR112022020423A2 (pt) | Compostos e métodos para modulação de splicing | |
BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
BR112018006298A2 (pt) | "adjunto compressível com fibras espaçadoras cruzadas" | |
CL2020000937A1 (es) | Anticuerpo multiespecífico. | |
BR112014028644A2 (pt) | Composições e métodos para modulação da expressão de atp2a2 | |
MX2022010681A (es) | Compuestos y metodos para modular el empalme. | |
BR112016014020A2 (pt) | Compostos moduladores de tetra-hidropiridopirazinas de gpr6, seus sais e os usos dos mesmos | |
BRPI0811926A8 (pt) | Composições herbicidas, processo para a preparação de uma composição herbicida, processo para o controle de vegetação indesejável e uso de um ácido graxo para estabilizar uma composição herbicida | |
BR112018002904A2 (pt) | sistemas de solvente de triamida alquiltiofosfórica e/ou dcd estabilizados por amina em altas temperaturas e uso em aplicações agrícolas | |
BR112018075201A2 (pt) | moduladores do receptor beta-3 adrenérgico úteis para o tratamento ou prevenção de distúrbios relacionados com os mesmos | |
BR112019000356A2 (pt) | compostos e métodos para modulação de smn2 | |
BR112022009723A2 (pt) | Anticorpos específicos para cd47, pd-l1, e usos dos mesmos | |
CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
BR112022008061A2 (pt) | Processo eficaz para síntese de 2-amino-5-cloro-n,3-dimetilbenzamida | |
BR112023018619A2 (pt) | Inibidores de heteroaril de calicreína plasmática | |
BR112023023223A2 (pt) | Degradadores de cdk2 e usos dos mesmos | |
CO2024002648A2 (es) | Compuestos y métodos para modular splicing | |
CO2024002647A2 (es) | Compuestos y métodos para modular el empalme | |
CR20220483A (es) | Compuestos y métodos para modular el empalme | |
AR120850A1 (es) | Moduladores de la necroptosis, procedimientos de cribado y composiciones farmacéuticas | |
CO2024004482A2 (es) | Composiciones moduladoras de la subunidad beta e de inhibina (inhbe) y métodos de uso de las mismas | |
BR112022000188A2 (pt) | Método para a preparação de 2-(fenilimino)-1,3-tiazolidin-4-onas |